Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05795595
PHASE1

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Sponsor: CRISPR Therapeutics AG

View on ClinicalTrials.gov

Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

Official title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2023-03-13

Completion Date

2025-09-18

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

BIOLOGICAL

CTX131

CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Locations (7)

Research Site 3

Duarte, California, United States

Research Site 7

Chicago, Illinois, United States

Research Site 6

Boston, Massachusetts, United States

Research Site 2

St Louis, Missouri, United States

Research Site 4

Durham, North Carolina, United States

Research Site 1

Nashville, Tennessee, United States

Research Site 5

Houston, Texas, United States